UA112230U - Спосіб лікування важкого абстинентного синдрому прямою транслюмбальною оксидацією - Google Patents
Спосіб лікування важкого абстинентного синдрому прямою транслюмбальною оксидацією Download PDFInfo
- Publication number
- UA112230U UA112230U UAU201605531U UAU201605531U UA112230U UA 112230 U UA112230 U UA 112230U UA U201605531 U UAU201605531 U UA U201605531U UA U201605531 U UAU201605531 U UA U201605531U UA 112230 U UA112230 U UA 112230U
- Authority
- UA
- Ukraine
- Prior art keywords
- ozone
- treatment
- oxidation
- syndrome
- direct
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000003647 oxidation Effects 0.000 title claims abstract description 8
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 8
- 208000011580 syndromic disease Diseases 0.000 title description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 13
- 206010048010 Withdrawal syndrome Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 230000006837 decompression Effects 0.000 claims description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 11
- 208000029650 alcohol withdrawal Diseases 0.000 description 9
- 206010012218 Delirium Diseases 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009593 lumbar puncture Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 206010048962 Brain oedema Diseases 0.000 description 3
- 208000006752 brain edema Diseases 0.000 description 3
- 230000002920 convulsive effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940053973 novocaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201605531U UA112230U (xx) | 2016-05-23 | 2016-05-23 | Спосіб лікування важкого абстинентного синдрому прямою транслюмбальною оксидацією |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201605531U UA112230U (xx) | 2016-05-23 | 2016-05-23 | Спосіб лікування важкого абстинентного синдрому прямою транслюмбальною оксидацією |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112230U true UA112230U (xx) | 2016-12-12 |
Family
ID=58044477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201605531U UA112230U (xx) | 2016-05-23 | 2016-05-23 | Спосіб лікування важкого абстинентного синдрому прямою транслюмбальною оксидацією |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA112230U (xx) |
-
2016
- 2016-05-23 UA UAU201605531U patent/UA112230U/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE102007009888A1 (de) | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen | |
| Seo et al. | Analysis of direct medical control conducted to 119 emergency medical technicians in an emergency medical information center | |
| Schultz et al. | Radiculomyelopathy following intrathecal instillation of methylene blue: A hazard reaffirmed | |
| UA112230U (xx) | Спосіб лікування важкого абстинентного синдрому прямою транслюмбальною оксидацією | |
| White et al. | Sequelae to pneumoencephalography | |
| YANG et al. | Efficacy of acupuncture in combination with medicine for mild cognitive impairment after cerebral infarction: a randomized controlled trial | |
| CN107854620B (zh) | 一种改善脑损伤后认知功能障碍的中药组合物及其应用 | |
| 조상호 et al. | Heart rate change while drowsy driving | |
| RU2233665C2 (ru) | Средство для лечения детского церебрального паралича | |
| RU2145895C1 (ru) | Способ лечения церебрального ишемического инсульта | |
| Shah et al. | A comparative study between levobupivacaine 0.5% plus lignocaine 2% or bupivacaine 0.5% plus lignocaine 2% for peribulbar block in cataract surgery | |
| Mishra et al. | A clinical comparison between bupivacaine midazolam combination and bupivacaine plain in brachial plexus block by supraclavicular approach | |
| Loranger et al. | Parkinsonism, L-dopa and intelligence | |
| RU2141325C1 (ru) | Способ лечения посттравматического иммунодефицита в остром периоде травматической болезни головного мозга | |
| RU2141359C1 (ru) | Способ лечения неврологических и ортопедо-травматологических патологий | |
| RU2502513C2 (ru) | Способ лечения больных с полиорганной патологией озонотерапией | |
| RU2178288C2 (ru) | Способ лечения заболеваний нервной системы | |
| RU2332157C1 (ru) | Способ диагностики поражения среднего мозга и глазодвигательного нерва | |
| Murthy et al. | Comparative study between Nalbuphine and Dexmedetomidine as an adjuvant to Ropivacaine for Caudal Block in children undergoing infra umbilical surgeries | |
| Liu et al. | Sedative Effects of Dexmedetomidine in Combination with Propofol in Patients with Atrial Fibrillation Undergoing Electrical Cardioversion following Catheter Ablation | |
| Zhang et al. | Effects of comprehensive rehabilitation on complications and long-term prognoses of patients in vegetative and minimal consciousness states. | |
| Gorinova et al. | P075 Long-term effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in daily practice of cystic fibrosis center in the Republic of Tatarstan | |
| RU2124875C1 (ru) | Способ лечения больных с частичной атрофией зрительных нервов | |
| Howard et al. | Disorders of Consciousness and Intensive Care Neurology | |
| SU1600775A1 (ru) | Способ лечени ишемического церебрального инсульта в остром периоде |